Description

CJC-1295 with DAC – 5 mg

(Growth Hormone Releasing Hormone Analog with Drug Affinity Complex)

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH 1-29) engineered to extend the half-life and duration of GHRH activity through covalent binding to plasma proteins. This modification allows for prolonged and stable stimulation of endogenous growth-hormone release in research models, distinguishing it from shorter-acting GHRH analogs.

The compound has been widely studied in preclinical and early-phase clinical research for its potential to enhance pulsatile growth-hormone secretion, support cellular regeneration, and improve metabolic and recovery-related parameters.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• GHRH receptor activation: Stimulates the anterior pituitary to release endogenous growth hormone (GH).

• DAC modification: The Drug Affinity Complex binds to albumin, extending peptide half-life and allowing for sustained GH release.

• Pulsatile GH secretion: Mimics natural growth-hormone rhythms, supporting downstream IGF-1 production.

• Cellular and tissue support: Promotes protein synthesis, cellular repair, and lipid metabolism via GH/IGF-1 pathways.

• Improved bioavailability: Reduces frequency of administration compared to non-DAC GHRH analogs.

---

Potential Benefits (Based on Preclinical Research):

• Sustained increase in GH and IGF-1 levels in experimental models

• Improved muscle recovery and tissue regeneration

• Enhanced lipid metabolism and body-composition modulation

• Investigated for potential anti-aging and cellular-repair effects

• Studied for synergy with GHRPs and other GH-secretagogues

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.